Search Results - "de Moor, Carl"

Psychosocial and demographic predictors of quality of life in a large sample of cancer patients by Parker, Patricia A., Baile, Walter F., Moor, Carl de, Cohen, Lorenzo

“…In recent years, there has been increasing emphasis on understanding how the cancer experience affects individuals' quality of life (QOL). The goal of this…”
Get full text

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings by Cohen, Lorenzo, de Moor, Carl A, Eisenberg, Peter, Ming, Eileen E, Hu, Henry

“…The present study sought to determine the prevalence of acute and delayed chemotherapy-induced nausea and vomiting (CINV) across ten community oncology…”
Get full text

Visualizing the target estimand in comparative effectiveness studies with multiple treatments by Simoneau, Gabrielle, Mitroiu, Marian, Debray, Thomas Pa, Wei, Wei, Wijn, Stan Rw, Magalhães, Joana Caldas, Bohn, Justin, Shen, Changyu, Pellegrini, Fabio, Moor, Carl de

“…Comparative effectiveness research using real-world data often involves pairwise propensity score matching to adjust for confounding bias. We show that…”
Get full text

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis by Kuhle, Jens, Plavina, Tatiana, Barro, Christian, Disanto, Giulio, Sangurdekar, Dipen, Singh, Carol M, de Moor, Carl, Engle, Bob, Kieseier, Bernd C, Fisher, Elizabeth, Kappos, Ludwig, Rudick, Richard A, Goyal, Jaya

“…Background: Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive…”
Get full text

Tobacco cessation education for pharmacists: Face-to-face presentations versus live webinars by Hudmon, Karen Suchanek, DrPH, MS, Hoch, Matthew A., PharmD, MS, Vitale, Frank M., MA, Wahl, Kimberly R., PharmD, Corelli, Robin L., PharmD, Moor, Carl de, PhD

“…Abstract Objective To assess the perceived effectiveness of tobacco cessation continuing education for pharmacists in face-to-face presentation versus live…”
Get full text

The effects of smoking deprivation and nicotine administration on emotional reactivity by Cinciripini, Paul M., Robinson, Jason D., Carter, Brian L., Lam, Cho, Wu, XiFeng, de Moor, Carl A., Baile, Walter F., Wetter, David W.

“…Although converging lines of evidence suggest that nicotine and mood are related at a fundamental biological level, this link has not been reliably…”
Get full text

The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review by Karim, Mohammad Ehsanul, Pellegrini, Fabio, Platt, Robert W, Simoneau, Gabrielle, Rouette, Julie, de Moor, Carl

“…Background: Propensity score (PS) analyses are increasingly used in multiple sclerosis (MS) research, largely owing to the greater availability of large…”
Get full text

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice by Foley, John, Xiong, Kuangnan, Hoyt, Tammy, Singh, Carol M, Riddle, Evan, de Moor, Carl, Plavina, Tatiana, Campbell, Nolan

“…Background: Serum levels of neurofilament light chain (sNfL) are a potentially useful biomarker for assessing the efficacy of multiple sclerosis (MS)…”
Get full text

018  Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab by Calabresi, Peter A, Kappos, Ludwig, Giovannoni, Gavin, Plavina, Tatiana, Koulinska, Irene, Edwards, Michael R, Kieseier, Bernd, Moor, Carl de, Fisher, Elizabeth

“…IntroductionNo evidence of disease activity (NEDA; no relapses, MRI activity, or Expanded Disability Status Scale worsening) is considered a multiple sclerosis…”
Get full text

A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis by Pellegrini, Fabio, Copetti, Massimiliano, Bovis, Francesca, Cheng, David, Hyde, Robert, de Moor, Carl, Kieseier, Bernd C, Sormani, Maria Pia

“…Background: Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are…”
Get full text

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring by Calabresi, Peter A, Arnold, Douglas L, Sangurdekar, Dipen, Singh, Carol M, Altincatal, Arman, de Moor, Carl, Engle, Bob, Goyal, Jaya, Deykin, Aaron, Szak, Suzanne, Kieseier, Bernd C, Rudick, Richard A, Plavina, Tatiana

“…Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis…”
Get full text

Recommendations for the use of propensity score methods in multiple sclerosis research by Simoneau, Gabrielle, Pellegrini, Fabio, Debray, Thomas PA, Rouette, Julie, Muñoz, Johanna, Platt, Robert W., Petkau, John, Bohn, Justin, Shen, Changyu, de Moor, Carl, Karim, Mohammad Ehsanul

“…Background: With many disease-modifying therapies currently approved for the management of multiple sclerosis, there is a growing need to evaluate the…”
Get full text

Digital Devices for Assessing Motor Functions in Mobility-Impaired and Healthy Populations: Systematic Literature Review by Guo, Christine C, Chiesa, Patrizia Andrea, de Moor, Carl, Fazeli, Mir Sohail, Schofield, Thomas, Hofer, Kimberly, Belachew, Shibeshih, Scotland, Alf

“…Background With the advent of smart sensing technology, mobile and wearable devices can provide continuous and objective monitoring and assessment of motor…”
Get full text

Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation by Jiang, Xiaotong, Shen, Changyu, Teunissen, Charlotte E, Wessels, Mark, Zetterberg, Henrik, Giovannoni, Gavin, Singh, Carol M, Caba, Bastien, Elliott, Colm, Fisher, Elizabeth, de Moor, Carl, Belachew, Shibeshih, Gafson, Arie R

“…Background: The clinical relevance of serum glial fibrillary acidic protein (sGFAP) concentration as a biomarker of MS disability progression independent of…”
Get full text

Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling by Pellegrini, Fabio, Copetti, Massimiliano, Sormani, Maria Pia, Bovis, Francesca, de Moor, Carl, Debray, Thomas PA, Kieseier, Bernd C

“…Background: There is an unmet need for precise methods estimating disease prognosis in multiple sclerosis (MS). Objective: Using advanced statistical modeling,…”
Get full text

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) by Mowry, Ellen M, Bermel, Robert A, Williams, James R, Benzinger, Tammie L S, de Moor, Carl, Fisher, Elizabeth, Hersh, Carrie M, Hyland, Megan H, Izbudak, Izlem, Jones, Stephen E, Kieseier, Bernd C, Kitzler, Hagen H, Krupp, Lauren, Lui, Yvonne W, Montalban, Xavier, Naismith, Robert T, Nicholas, Jacqueline A, Pellegrini, Fabio, Rovira, Alex, Schulze, Maximilian, Tackenberg, Björn, Tintore, Mar, Tivarus, Madalina E, Ziemssen, Tjalf, Rudick, Richard A

“…Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is the first example of a learning health system in multiple sclerosis (MS)…”
Get full text

Methods for comparative effectiveness based on time to confirmed disability progression with irregular observations in multiple sclerosis by Debray, Thomas PA, Simoneau, Gabrielle, Copetti, Massimiliano, Platt, Robert W, Shen, Changyu, Pellegrini, Fabio, de Moor, Carl

“…Real-world data sources offer opportunities to compare the effectiveness of treatments in practical clinical settings. However, relevant outcomes are often…”
Get full text

The effects of type of surgery and time on psychological adjustment in women after breast cancer treatment by Cohen, L, Hack, T F, de Moor, C, Katz, J, Goss, P E

“…The aim of the present study was to examine whether type of surgery, age, and time since surgery influenced psychological distress and quality of life (QOL) in…”
Get full text

Time-dependence of hazard ratios for prognostic factors in primary breast cancer by Hilsenbeck, S G, Ravdin, P M, de Moor, C A, Chamness, G C, Osborne, C K, Clark, G M

“…Some prognostic factors, such as steroid receptors, appear strongly related to outcome in early studies with short follow-up, but as follow-up matures the…”
Get full text

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics by Hersh, Carrie M, Altincatal, Arman, Belviso, Nicholas, Kapadia, Shivani, de Moor, Carl, Rudick, Richard, Williams, James Rhys, Miller, Catherine, Koulinska, Irene

“…Background Prior studies suggest comparable effectiveness of dimethyl fumarate (DMF) and fingolimod (FTY) in multiple sclerosis (MS) using relapse, Expanded…”
Get full text